CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
一例 CAR-T 细胞治疗后致死性暴发性脑水肿
英文原题：A Case of Fulminant Cerebral Edema Leading to Death After Chimeric Antigen Receptor T-Cell Therapy.
查看英文原题
A Case of Fulminant Cerebral Edema Leading to Death After Chimeric Antigen Receptor T-Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法改变了难治性B细胞恶性肿瘤治疗，但会使患者面临放大免疫反应所致的副作用风险。暴发性脑水肿（FCE）是CAR-T 治疗后最罕见但最具破坏性的副作用之一。由于罕见，FCE尚未得到充分表征，其发生相关危险因素也尚未完全明确。本文报告一例42岁男性在CAR-T 细胞输注后死于FCE的病例，旨在更好理解输注前后哪些患者发生FCE的风险可能较高。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has transformed treatment of refractory B-cell malignancies; however, treatment puts patients at risk for side effects secondary to the amplified immune response it induces. Fulminant cerebral edema (FCE) is one of the rarest, yet most devastating side effects following CAR T-cell therapy. Due to this rarity, FCE has not been well characterized and the risk factors associated with its development are not fully understood.
Here, we present a case of a 42-year-old male who passed away from FCE following CAR T-cell infusion with the primary goal to better understand which patients are at higher risk of developing FCE before and after infusion.
论文信息
- 作者
- Hickmann K、DiLeo R、Faringer K、Peterson C、Khan C、Samhouri Y
- 第一作者单位
- Drexel University College of Medicine, Philadelphia, PA, USA.United States
- 通讯作者单位
- Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.United States
- 文献类型
- 病例报告
- 期刊
- Journal of hematology2024 Dec
- 原文标识
- PubMed 39697685 · DOI 10.14740/jh1367
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →